GO
Loading...

Amgen Inc

More

  • Midday Glance: Biotechnology companies Friday, 12 Dec 2014 | 1:18 PM ET

    Amgen Inc. rose$. 25 or. 1 percent, to $166.33. Biogen Idec rose $1.12 or. 3 percent, to $343.45. Celgene Corp. fell$. 99 or. 8 percent, to $115.75.

  • Early Glance: Biotechnology companies Friday, 12 Dec 2014 | 10:31 AM ET

    Amgen Inc. rose$. 24 or. 1 percent, to $166.32. Biogen Idec rose $3.18 or. 9 percent, to $345.51. Celgene Corp. fell$. 17 or. 1 percent, to $116.57.

  • ZURICH, Dec 12- Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson& Johnson's Stelara. The data follows results last year showing Cosentyx, also known as secukinumab, was superior to Amgen's Embrel in a head-to-head study. Other drugmakers working on new...

  • Final Glance: Biotechnology companies Thursday, 11 Dec 2014 | 6:02 PM ET

    Amgen Inc. rose$. 69 or. 4 percent, to $166.08. Biogen Idec fell $1.26 or. 4 percent, to $342.33. Celgene Corp. rose $1.10 or 1.0 percent, to $116.74.

  • Midday Glance: Biotechnology companies Thursday, 11 Dec 2014 | 1:18 PM ET

    Amgen Inc. rose $2.69 or 1.6 percent, to $168.08. Biogen Idec rose $3.88 or 1.1 percent, to $347.47. Celgene Corp. rose $2.16 or 1.9 percent, to $117.80.

  • Early Glance: Biotechnology companies Thursday, 11 Dec 2014 | 11:28 AM ET

    Amgen Inc. rose $2.53 or 1.5 percent, to $167.92. Biogen Idec rose $2.90 or. 8 percent, to $346.49. Celgene Corp. rose $1.91 or 1.7 percent, to $117.55.

  • CHICAGO, Dec 10- Small startup NextCode Health will use gene-hunting tools pioneered by Iceland's Decode Genetics to help a leading U.S. pediatric hospital identify causes of rare diseases in children, marking the latest foray of genetic sequencing into routine medical practice. Cambridge, Massachusetts- based NextCode, a Decode spin-off, has signed a deal...

  • Final Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 6:09 PM ET

    Amgen Inc. fell $4.00 or 2.4 percent, to $165.39. Biogen Idec fell $4.02 or 1.2 percent, to $343.59. Celgene Corp. fell $3.04 or 2.6 percent, to $115.64.

  • Midday Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 1:18 PM ET

    Amgen Inc. fell $1.19 or. 7 percent, to $168.20. Biogen Idec fell $1.82 or. 5 percent, to $345.79. Celgene Corp. fell$. 97 or. 8 percent, to $117.71.

  • Early Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 10:41 AM ET

    Amgen Inc. rose$. 07 or percent, to $169.46. Biogen Idec fell$. 17 or percent, to $347.44. Celgene Corp. fell$. 39 or. 3 percent, to $118.29.

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • Final Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 6:10 PM ET

    Amgen Inc. fell $2.25 or 1.3 percent, to $169.39. Biogen Idec rose $3.56 or 1.0 percent, to $347.61. Celgene Corp. rose$. 49 or. 4 percent, to $118.68.

  • Midday Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 1:21 PM ET

    Amgen Inc. fell $2.16 or 1.3 percent, to $169.48. Biogen Idec fell$. 23 or. 1 percent, to $343.82. Celgene Corp. rose$. 35 or. 3 percent, to $118.54.

  • Early Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 10:21 AM ET

    Amgen Inc. fell $2.53 or 1.5 percent, to $169.11. Biogen Idec fell $2.51 or. 7 percent, to $341.54. Celgene Corp. fell $1.02 or. 9 percent, to $117.17.

  • Final Glance: Biotechnology companies Monday, 8 Dec 2014 | 6:02 PM ET

    Amgen Inc. rose $2.40 or 1.4 percent, to $171.64. Biogen Idec rose $3.18 or. 9 percent, to $344.05. Celgene Corp. rose $4.06 or 3.6 percent, to $118.19.

  • McDonald's and Sony are big market movers Monday, 8 Dec 2014 | 4:41 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. McDonald's Corp., down $3.70 to $92.61. Sony Corp., down $1.01 to $21.15.

  • Midday Glance: Biotechnology companies Monday, 8 Dec 2014 | 1:20 PM ET

    Amgen Inc. rose $3.10 or 1.8 percent, to $172.34. Biogen Idec rose $3.09 or. 9 percent, to $343.96. Celgene Corp. rose $4.42 or 3.9 percent, to $118.55.

  • Amgen's bone drug Xgeva gets new approval Monday, 8 Dec 2014 | 11:21 AM ET

    NEW YORK— Amgen's Xgeva, which is used to treat bone disorders related to cancer, received an additional U.S. marketing approval. Amgen said hypercalcemia of malignancy is considered an orphan disease, meaning there are fewer than 200,000 patients in the U.S. Shares of Amgen Inc. rose $2.21 to $171.45 in morning trading.

  • Early Glance: Biotechnology companies Monday, 8 Dec 2014 | 10:22 AM ET

    Amgen Inc. rose $2.22 or 1.3 percent, to $171.46. Biogen Idec rose $4.43 or 1.3 percent, to $345.30. Celgene Corp. rose $3.86 or 3.4 percent, to $117.99.

  • Sandoz loses bid to shield psoriasis drug Friday, 5 Dec 2014 | 2:09 PM ET

    Dec 5- The top U.S. patent appeals court has upheld the dismissal of a lawsuit brought by Sandoz Inc that sought to shield its planned version of Amgen Inc's psoriasis and arthritis drug Enbrel from patent lawsuits. Taranto only ruled that the lawsuit against Amgen was premature because Sandoz had not yet sought approval for the drug from the U.S. Food and Drug...